The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.
ZhangX, ChuaiY, NieW, et al.Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev2017;11:CD012035.
ZhangX, ChuaiY, NieW, Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. Cochrane Database Syst Rev 2017;11:CD012035.29178132)| false
Al-SamkariH, ParnesAD, GoodarziK, A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. Haematologica 2021;106:1148–1157.3249923910.3324/haematol.2020.251900)| false
ShawJL, NielsonCM, ParkJK, The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021;106:662–672.10.1111/ejh.13595)| false
Al-SamkariH, MarshallAL, GoodarziK, The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica 2018;103:e169–172.10.3324/haematol.2017.18016629242295)| false
AlkhouriN, ImawariM, IzumiN, et al.Lusutrombopag is safe and efficacious for treatment of thrombocytopenia in patients with and without hepatocellular carcinoma. Clin Gastroenterol Hepatol2020;18: 2600–2608.e1.
AlkhouriN, ImawariM, IzumiN, Lusutrombopag is safe and efficacious for treatment of thrombocytopenia in patients with and without hepatocellular carcinoma. Clin Gastroenterol Hepatol 2020;18: 2600–2608.e1.10.1016/j.cgh.2020.03.03232205226)| false
MengF, ChenX, YuS, Safety and efficacy of eltrombopag and romiplostim in myelodysplastic syndromes: a systematic review and meta-analysis. Front Oncol 2020;10:582686.10.3389/fonc.2020.58268633324559)| false
MittelmanM, PlatzbeckerU, AfanasyevB, et al.Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol2018;5:e34–43.
Al-SamkariH, Kolb-SieleckiJ, SafinaSZ, et al.Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo- controlled, phase 3 trial. Lancet Haematol2022;9:e179–189.
AhmedS, BashirQ, BassettR, et al.Eltrombopag for post-transplantation thrombocytopenia: results of phase II randomized, double-blind, placebo-controlled trial. Transplant Cell Ther2021;27:430.e431–430.e7.